AIGH Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

AIGH Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,200,000	Closed	-$11.2M	–	59
2026 Q1	$11.2M	Buy	+1,200,000	New	+$10.8M	1.53%	20
2025 Q4	–	Sell	-1,231,932	Closed	-$11.7M	–	45
2025 Q3	$11.7M	Buy	1,231,932 +313,039	+34%	+$3.14M	3.3%	11
2025 Q2	$8.1M	Sell	918,893 -519,216	-36%	-$4.21M	3.64%	11
2025 Q1	$10.8M	Buy	1,438,109 +649,495	+82%	+$5.16M	4.46%	7
2024 Q4	$6.58M	Buy	+788,614	New	+$6.73M	2.06%	19
2024 Q3	–	Sell	-181,673	Closed	-$890K	–	47
2024 Q2	$890K	Buy	+181,673	New	+$861K	0.28%	31

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIGH Capital Management's ZVRA Position: Q2 2026 in Review

AIGH Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 1,200,000 shares — an estimated $11.2M sold.

AIGH Capital Management first reported a position in ZVRA in Q2 2024 and held it in 6 quarters. The position peaked at $11.7M in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

AIGH Capital Management reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
AIGH Capital Management sold 1,200,000 Zevra Therapeutics shares in Q2 2026, an estimated $11.2M.
AIGH Capital Management first reported a position in Zevra Therapeutics in Q2 2024 and held it in 6 quarters.
AIGH Capital Management's Zevra Therapeutics position peaked at $11.7M in Q3 2025.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on AIGH Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.